Does Medicare Cover the Tirzepatide Cost for Weight Management?

The Short Answer: It Depends on Your Diagnosis

Medicare coverage for tirzepatide is not straightforward. As of 2024, Medicare Part D plans cover tirzepatide (brand name Mounjaro) when prescribed for type 2 diabetes. However, when the same drug is prescribed under the brand name Zepbound specifically for chronic weight management, coverage becomes significantly more complicated. The reason comes down to a decades-old federal exclusion that blocks Medicare from covering drugs approved solely for weight loss or obesity treatment.

The Federal Exclusion That Blocks Obesity Drug Coverage

The 1997 Balanced Budget Act explicitly excluded weight-loss drugs from Medicare Part D coverage. This exclusion was written long before GLP-1 and GIP receptor agonists existed, but it applies to them regardless. When the FDA approved tirzepatide under the brand name Zepbound in November 2023 for chronic weight management in adults with obesity or overweight with at least one weight-related condition, that approval effectively placed it in a category Medicare Part D plans are prohibited from covering for the weight-management indication alone.

This creates a notable split: the same molecule, the same injection, the same tirzepatide cost in terms of list price — but coverage outcomes diverge based entirely on what the prescribing diagnosis code says. A patient with type 2 diabetes who also has obesity may receive Part D coverage under Mounjaro. A patient with obesity alone, without a diabetes diagnosis, faces a much harder road.

What Medicare Part D Plans Currently Cover

Mounjaro for Type 2 Diabetes

When tirzepatide is prescribed and billed as Mounjaro for type 2 diabetes management, most Medicare Part D formularies include it, though tier placement varies by plan. Patients typically encounter step therapy requirements, meaning the plan may require trying and failing a cheaper diabetes medication first. Out-of-pocket costs depend on the specific plan's cost-sharing structure, but the Medicare Prescription Drug Inflation Rebate and the Inflation Reduction Act's $2,000 annual out-of-pocket cap (fully in effect as of 2025) offer meaningful protection once patients reach catastrophic coverage.

Zepbound for Weight Management

For beneficiaries who do not have type 2 diabetes, Zepbound is not covered by Medicare Part D under current law. This leaves many patients paying full list price, which runs approximately $1,000 to $1,100 per month before any discounts — a tirzepatide cost that is simply unmanageable for most people on fixed incomes.

Proposed Changes: The Treat and Reduce Obesity Act

Congress has repeatedly introduced the Treat and Reduce Obesity Act, which would eliminate the 1997 exclusion and allow Medicare Part D to cover FDA-approved obesity treatments, including tirzepatide. As of early 2026, the legislation has not passed, but it continues to gain bipartisan support as the clinical evidence for GLP-1 and GIP agonists in reducing cardiovascular events, sleep apnea, and other comorbidities grows stronger. If passed, the bill would represent the most significant shift in Medicare obesity drug coverage in decades.

Strategies to Reduce Tirzepatide Cost While Waiting for Coverage

• Manufacturer savings programs: Eli Lilly offers the Lilly Cares Foundation program and commercial savings cards, but most explicitly exclude Medicare beneficiaries from eligibility.
• Medicare Advantage plans: Some Medicare Advantage (Part C) plans have added supplemental obesity drug benefits, but availability is limited and varies sharply by geography and plan sponsor.
• State Medicaid programs: If a beneficiary is dual-eligible for Medicare and Medicaid, their state Medicaid plan may cover obesity drugs depending on state-specific formulary decisions.
• Compounded tirzepatide: During FDA shortage periods, some compounding pharmacies have offered tirzepatide at lower prices, though the FDA has indicated it intends to remove tirzepatide from the shortage list, which would restrict compounding access.
• Appealing through a physician: If a patient has obesity-related comorbidities such as hypertension, sleep apnea, or fatty liver disease, a prescriber may document a metabolic indication that supports a broader clinical case for coverage.

What to Do Right Now If You Are on Medicare

Start by contacting your Part D or Medicare Advantage plan directly to ask whether tirzepatide is on your formulary and under what diagnosis codes it is covered. Ask your physician whether your medical record supports a type 2 diabetes diagnosis or another covered indication. If you are denied coverage, request a formal coverage determination in writing, which triggers an appeals process with defined timelines. Patient advocacy organizations focused on obesity medicine can also provide guidance on navigating these appeals and staying current on legislative developments that may shift coverage rules in the near future.